Protara Therapeutics (TARA) Competitors

Protara Therapeutics logo
$2.32 -0.07 (-2.73%)
As of 11:23 AM Eastern
This is a fair market value price provided by Massive. Learn more.

TARA vs. NGNE, PBYI, ENTX, CLYM, and VALN

Should you buy Protara Therapeutics stock or one of its competitors? Protara Therapeutics's main competitors and comparable companies include Neurogene (NGNE), Puma Biotechnology (PBYI), Entera Bio (ENTX), Climb Bio (CLYM), and Valneva (VALN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Protara Therapeutics compare to Neurogene?

Protara Therapeutics (NASDAQ:TARA) and Neurogene (NASDAQ:NGNE) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk.

Protara Therapeutics presently has a consensus target price of $26.25, indicating a potential upside of 1,002.94%. Neurogene has a consensus target price of $79.57, indicating a potential upside of 241.51%. Given Protara Therapeutics' higher probable upside, equities analysts clearly believe Protara Therapeutics is more favorable than Neurogene.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Protara Therapeutics
1 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.75
Neurogene
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
2 Strong Buy rating(s)
3.00

38.1% of Protara Therapeutics shares are held by institutional investors. Comparatively, 52.4% of Neurogene shares are held by institutional investors. 7.6% of Protara Therapeutics shares are held by insiders. Comparatively, 11.7% of Neurogene shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Protara Therapeutics has a beta of 1.54, meaning that its share price is 54% more volatile than the broader market. Comparatively, Neurogene has a beta of 1.75, meaning that its share price is 75% more volatile than the broader market.

Protara Therapeutics has higher earnings, but lower revenue than Neurogene. Neurogene is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Protara TherapeuticsN/AN/A-$57.44M-$1.39N/A
Neurogene$930K518.61-$90.35M-$5.09N/A

In the previous week, Protara Therapeutics and Protara Therapeutics both had 17 articles in the media. Protara Therapeutics' average media sentiment score of 0.95 beat Neurogene's score of 0.74 indicating that Protara Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Protara Therapeutics
4 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Neurogene
3 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Neurogene's return on equity of -44.36% beat Protara Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Protara TherapeuticsN/A -46.15% -42.75%
Neurogene N/A -44.36%-40.61%

Summary

Neurogene beats Protara Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Protara Therapeutics compare to Puma Biotechnology?

Puma Biotechnology (NASDAQ:PBYI) and Protara Therapeutics (NASDAQ:TARA) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

61.3% of Puma Biotechnology shares are held by institutional investors. Comparatively, 38.1% of Protara Therapeutics shares are held by institutional investors. 22.2% of Puma Biotechnology shares are held by insiders. Comparatively, 7.6% of Protara Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Puma Biotechnology has higher revenue and earnings than Protara Therapeutics. Protara Therapeutics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Puma Biotechnology$231.83M1.64$31.11M$0.4615.96
Protara TherapeuticsN/AN/A-$57.44M-$1.39N/A

Puma Biotechnology currently has a consensus price target of $6.00, indicating a potential downside of 18.26%. Protara Therapeutics has a consensus price target of $26.25, indicating a potential upside of 1,002.94%. Given Protara Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Protara Therapeutics is more favorable than Puma Biotechnology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Puma Biotechnology
0 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Protara Therapeutics
1 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.75

In the previous week, Protara Therapeutics had 9 more articles in the media than Puma Biotechnology. MarketBeat recorded 17 mentions for Protara Therapeutics and 8 mentions for Puma Biotechnology. Protara Therapeutics' average media sentiment score of 0.95 beat Puma Biotechnology's score of 0.50 indicating that Protara Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Puma Biotechnology
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Protara Therapeutics
4 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Puma Biotechnology has a net margin of 10.26% compared to Protara Therapeutics' net margin of 0.00%. Puma Biotechnology's return on equity of 17.50% beat Protara Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Puma Biotechnology10.26% 17.50% 11.83%
Protara Therapeutics N/A -46.15%-42.75%

Puma Biotechnology has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market. Comparatively, Protara Therapeutics has a beta of 1.54, suggesting that its share price is 54% more volatile than the broader market.

Summary

Puma Biotechnology beats Protara Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Protara Therapeutics compare to Entera Bio?

Entera Bio (NASDAQ:ENTX) and Protara Therapeutics (NASDAQ:TARA) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends, earnings and media sentiment.

14.1% of Entera Bio shares are owned by institutional investors. Comparatively, 38.1% of Protara Therapeutics shares are owned by institutional investors. 3.7% of Entera Bio shares are owned by company insiders. Comparatively, 7.6% of Protara Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Protara Therapeutics had 14 more articles in the media than Entera Bio. MarketBeat recorded 17 mentions for Protara Therapeutics and 3 mentions for Entera Bio. Protara Therapeutics' average media sentiment score of 0.95 beat Entera Bio's score of 0.62 indicating that Protara Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Entera Bio
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Protara Therapeutics
4 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Entera Bio's return on equity of -38.55% beat Protara Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Entera BioN/A -38.55% -36.15%
Protara Therapeutics N/A -46.15%-42.75%

Entera Bio has higher revenue and earnings than Protara Therapeutics. Entera Bio is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Entera Bio$40K13,147.57-$11.44M-$0.39N/A
Protara TherapeuticsN/AN/A-$57.44M-$1.39N/A

Entera Bio has a beta of 1.48, indicating that its share price is 48% more volatile than the broader market. Comparatively, Protara Therapeutics has a beta of 1.54, indicating that its share price is 54% more volatile than the broader market.

Entera Bio presently has a consensus target price of $9.60, indicating a potential upside of 217.88%. Protara Therapeutics has a consensus target price of $26.25, indicating a potential upside of 1,002.94%. Given Protara Therapeutics' higher probable upside, analysts plainly believe Protara Therapeutics is more favorable than Entera Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Entera Bio
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.83
Protara Therapeutics
1 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.75

Summary

Entera Bio and Protara Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Protara Therapeutics compare to Climb Bio?

Protara Therapeutics (NASDAQ:TARA) and Climb Bio (NASDAQ:CLYM) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, media sentiment, risk, dividends and valuation.

Protara Therapeutics has a beta of 1.54, indicating that its stock price is 54% more volatile than the broader market. Comparatively, Climb Bio has a beta of 0.01, indicating that its stock price is 99% less volatile than the broader market.

Climb Bio is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Protara TherapeuticsN/AN/A-$57.44M-$1.39N/A
Climb BioN/AN/A-$59.85M-$0.82N/A

Protara Therapeutics presently has a consensus price target of $26.25, suggesting a potential upside of 1,002.94%. Climb Bio has a consensus price target of $28.14, suggesting a potential upside of 183.33%. Given Protara Therapeutics' higher possible upside, equities research analysts plainly believe Protara Therapeutics is more favorable than Climb Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Protara Therapeutics
1 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.75
Climb Bio
1 Sell rating(s)
0 Hold rating(s)
12 Buy rating(s)
2 Strong Buy rating(s)
3.00

In the previous week, Protara Therapeutics had 6 more articles in the media than Climb Bio. MarketBeat recorded 17 mentions for Protara Therapeutics and 11 mentions for Climb Bio. Protara Therapeutics' average media sentiment score of 0.95 beat Climb Bio's score of 0.72 indicating that Protara Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Protara Therapeutics
4 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Climb Bio
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

38.1% of Protara Therapeutics shares are held by institutional investors. Comparatively, 69.8% of Climb Bio shares are held by institutional investors. 7.6% of Protara Therapeutics shares are held by company insiders. Comparatively, 2.6% of Climb Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Climb Bio's return on equity of -30.57% beat Protara Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Protara TherapeuticsN/A -46.15% -42.75%
Climb Bio N/A -30.57%-29.55%

Summary

Climb Bio beats Protara Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Protara Therapeutics compare to Valneva?

Valneva (NASDAQ:VALN) and Protara Therapeutics (NASDAQ:TARA) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation and media sentiment.

Protara Therapeutics has a net margin of 0.00% compared to Valneva's net margin of -110.33%. Protara Therapeutics' return on equity of -46.15% beat Valneva's return on equity.

Company Net Margins Return on Equity Return on Assets
Valneva-110.33% -153.20% -39.50%
Protara Therapeutics N/A -46.15%-42.75%

Valneva has a beta of 1.37, suggesting that its stock price is 37% more volatile than the broader market. Comparatively, Protara Therapeutics has a beta of 1.54, suggesting that its stock price is 54% more volatile than the broader market.

11.4% of Valneva shares are owned by institutional investors. Comparatively, 38.1% of Protara Therapeutics shares are owned by institutional investors. 14.9% of Valneva shares are owned by company insiders. Comparatively, 7.6% of Protara Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valneva presently has a consensus target price of $9.30, suggesting a potential upside of 64.60%. Protara Therapeutics has a consensus target price of $26.25, suggesting a potential upside of 1,002.94%. Given Protara Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Protara Therapeutics is more favorable than Valneva.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Valneva
2 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.67
Protara Therapeutics
1 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.75

Protara Therapeutics has lower revenue, but higher earnings than Valneva. Valneva is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Valneva$197.56M2.72-$130.33M-$2.11N/A
Protara TherapeuticsN/AN/A-$57.44M-$1.39N/A

In the previous week, Protara Therapeutics had 7 more articles in the media than Valneva. MarketBeat recorded 17 mentions for Protara Therapeutics and 10 mentions for Valneva. Protara Therapeutics' average media sentiment score of 0.95 beat Valneva's score of 0.58 indicating that Protara Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Valneva
2 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Protara Therapeutics
4 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Protara Therapeutics beats Valneva on 11 of the 14 factors compared between the two stocks.

Get Protara Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TARA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TARA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TARA vs. The Competition

MetricProtara TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$142.54M$4.03B$7.76B$11.52B
Dividend YieldN/A3.62%2.46%4.42%
P/E Ratio-1.6723.8834.2129.69
Price / SalesN/A16.208.475.59
Price / CashN/A26.3721.9322.50
Price / Book1.014.084.303.66
Net Income-$57.44M-$22.88M$3.52B$392.29M
7 Day Performance-4.73%-7.26%-5.29%-4.21%
1 Month Performance-0.22%-6.09%-4.26%-6.68%
1 Year Performance-58.44%-6.92%-1.48%-7.19%

Protara Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TARA
Protara Therapeutics
2.8511 of 5 stars
$2.32
-2.7%
$26.25
+1,033.9%
-56.8%$142.54MN/AN/A51
NGNE
Neurogene
2.373 of 5 stars
$26.00
+2.7%
$80.29
+208.8%
+2.3%$551.91M$930KN/A131
PBYI
Puma Biotechnology
1.2199 of 5 stars
$8.40
+1.8%
$6.00
-28.6%
+50.1%$551.82M$228.40M18.26179
ENTX
Entera Bio
2.3489 of 5 stars
$3.25
+3.5%
$9.60
+195.4%
+11.4%$540.90M$40KN/A21
CLYM
Climb Bio
2.9941 of 5 stars
$11.01
+7.0%
$28.14
+155.6%
+422.8%$535.88MN/AN/A29

Related Companies and Tools


This page (NASDAQ:TARA) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners